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Objectives: We investigated the effect of dextrorphan, an N-methyl-D-aspartate
receptor antagonist, on the reduction of ischemic spinal cord injury and the safe
clamping time after various methods of administration.
Methods: Spinal cord ischemia was induced in New Zealand White rabbits by
infrarenal aortic clamping and animals were divided into 5 groups. Group A (n =
15) received simple clamping. Groups B (n = 20) and C (n = 35) received dextrorphan
pretreatment (10 mg/kg), followed by continuous intravenous or intra-aortic infusion
(1 mg/min), respectively. Group D (n = 25) received the same dextrorphan pretreat-
ment and bolus intra-aortic injection at clamping (1 mg per minute of clamping time).
Group E (n = 15) received bolus intrathecal injection of dextrorphan (0.2 mg/kg). Each
dextrorphan-treated group had a small group of control animals (n = 5). The neurologic
status was assessed by the Johnson score (5 = normal, 0 = paraplegic) 48 hours after
unclamping, and animals were put to death for histopathologic examination.
Results: All dextrorphan-treated groups showed better neurologic function than the
respective control animals (P < .001 vs groups B, C, and D; P = .014 vs group E).
The order of efficacy of dextrorphan (as revealed by the average of neurologic sta-
tus) was as follows: group C > group D (P = .017, after 50 minutes of clamping),
group D > group B (P = .014, after 45 minutes of clamping), and group B > group
E (P < .001, after 40 minutes of clamping). Histopathologic findings did not nec-
essarily correspond with hind-limb neurologic function.
Conclusions: Dextrorphan reduced the physical findings associated with ischemic
spinal cord injury, and continuous intra-aortic infusion prolonged the safe clamping
time significantly more than delivery by other routes.
Spinal cord ischemia is a severe complication of surgery on the descend-ing aorta and thoracoabdominal aorta that has a major effect on the post-operative quality of life.1,2 Once the spinal cord becomes ischemic, theexcitatory neurotransmitter glutamate is released from neuronalsynapses and activates intracellular Ca2+ influx. This Ca2+ influx isthought to trigger a chain of reactions that lead to neuronal death.3
Protection of the central nervous system with noncompetitive antagonists of N-
methyl-D-aspartate (NMDA), a glutamate receptor subtype, has been documented.4,5
Many drugs, including, dextromethorphan,6 dextrorphan,7-9 memantine,10 and
riluzole,11 are known as noncompetitive NMDA receptor antagonists and have been
shown to reduce paraplegia after spinal cord ischemia. Dextrorphan has been shown
to protect the spinal cord against 158 to 259 minutes of ischemia. However, no study
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demonstrating the maximum length of the safe clamping
time achievable by dextrorphan has been reported. We
examined the effect of dextrorphan on spinal cord ischemic
injury and sought to prolong the safe aortic clamping time
by testing various drug delivery methods, such as intra-
venous infusion, intra-aortic injection, and intrathecal
injection.
Materials and Methods
Animal Care and Surgical Procedure
We used male New Zealand White rabbits weighing 2.5 to 3.5 kg.
All animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press, revised
1996, and the “Guidelines for Animal Experimentation” of
Hamamatsu University School of Medicine.
Animals were randomly divided into 5 groups. Group A (n =
15) received simple infrarenal aortic clamping, group B (n = 20)
received continuous intravenous infusion of dextrorphan, group C
(n = 35) received continuous intra-aortic infusion of dextrorphan,
group D (n = 25) received a bolus intra-aortic injection of dextror-
phan, and group E (n = 15) received a bolus intrathecal injection of
dextrorphan. Each dextrorphan-treated group had a small group of
control animals (n = 5 each), which were given an equal amount
of normothermic (24°C) saline solution for 30 minutes after
clamping. The rabbits were anesthetized with intravenous sodium
pentobarbital (25 mg/kg). Intravenous vecuronium bromide (0.1
mg/kg) was also used in group E as a muscle relaxant to avoid
movement during needle insertion into the spinal canal. The ani-
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mals were allowed to breathe spontaneously except in group E, in
which tracheotomy and mechanical ventilation were necessitated
by use of the muscle relaxant. All groups received 0.5% lidocaine
hydrochloride at the site of skin incision as local anesthesia. After
the incision had been made in the neck, an arterial line was secured
in the left common carotid artery with a 24-gauge catheter for
monitoring of the arterial pressure proximal to the site of clamp-
ing. A continuous intravenous infusion line was secured in the left
external jugular vein with a 24-gauge catheter. A continuous intra-
aortic infusion line was established in the right femoral artery with
a 20-gauge catheter, the tip of which extended to the infrarenal
abdominal aorta. Rectal temperature was continuously monitored
with a flexible probe (Terumo Medical Corporation, Tokyo,
Japan). The animal was placed in the supine position and the
infrarenal abdominal aorta was exposed through a transperitoneal
approach. After intravenous or intra-aortic administration of
heparin (100 U/kg), spinal cord ischemia was induced by cross-
clamping the abdominal aorta just distal to the origin of the renal
arteries and just proximal to the aortic bifurcation. Each of the 5
groups was subdivided into a number of separate cohorts on the
basis of the duration of clamping time. The subgroups, which con-
sisted of 5 animals each, were constructed in the following way:
group A, at 20, 25, and 30 minutes of clamping; group B, every 5
minutes from 30 to 45 minutes of clamping; group C, every 5 min-
utes from 30 to 60 minutes of clamping; group D, every 5 minutes
from 30 to 50 minutes of clamping; and group E, at 25, 30, and 40
minutes of clamping.
Drug Delivery
Dextrorphan (Hoffman-La Roche Inc, Basel, Switzerland) was dis-
solved in saline solution at a concentration of 10 mg/mL for the treat-
Figure 1. Schematic representation of experimental protocol. Group A received simple infrarenal aortic clamp-
ing; group B, continuous intravenous infusion of dextrorphan; group C, continuous intra-aortic infusion of dex-
trorphan; group D, bolus intra-aortic injection of dextrorphan; and group E, bolus intrathecal injection of
dextrorphan. DX, Dextrorphan; IV, intravenous infusion; IA, intra-aortic infusion; CIV, continuous intravenous
infusion; CIA, continuous intra-aortic infusion; IT, intrathecal injection.
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ment of groups B, C, and D. For group E, a 1-mg/mL concentration
of dextrorphan was prepared. In group B, dextrorphan pretreatment
(10 mg/kg) was done through the external jugular vein catheter 5 min-
utes before aortic clamping. This was followed by continuous intra-
venous infusion of dextrorphan at a rate of 1 mg/min with an infusion
pump (Terumo) until 15 minutes after unclamping. Group C received
continuous intra-aortic infusion of dextrorphan into the closed seg-
ment of the abdominal aorta after pretreatment (10 mg/kg) through
the catheter in the right femoral artery 5 minutes before aortic clamp-
ing. Group D had similar dextrorphan pretreatment to group C and
then received a bolus injection of dextrorphan (1 mg per minute of
clamping time) into the closed segment of the aorta through the same
route as group C immediately after clamping, as well as an additional
15 mg of dextrorphan after unclamping. In group E, a tracheotomy
was done to start mechanical ventilation. Then laminectomy was per-
formed via a posterior approach in the left lateral position. The spin-
ous processes of L5 were removed, and the surrounding structures
were dissected until the epidural fat was exposed. A bolus dose of
dextrorphan (0.2 mg/kg) was given intrathecally 30 minutes before
spinal cord ischemia was induced (Figure 1).
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Neurologic Evaluation
Neurologic status was scored by assessment of hind-limb motor
function 48 hours after unclamping according to the Johnson neu-
rologic recovery scale12: 0 = hind-limb paralysis; 1 = severe para-
paresis; 2 = functional movement, no hopping; 3 = ataxic hopping;
4 = minimal ataxia; 5 = normal.
Histopathologic Examination
After these assessments, animals were put to death with an over-
dose of intravenous sodium pentobarbital. The lumbar spinal cord
(L4 to L6) was quickly removed and fixed overnight in 10%
buffered formalin. Paraffin-embedded spinal cord sections were
processed for hematoxylin and eosin staining, and histopathologic
evaluation, including a count of the remaining neurons per section
in the gray matter, was performed under a light microscope.
Statistical Analysis
The average neurologic recovery score was calculated and was
expressed as mean ± standard deviation (SD). Statistical analysis
of the neurologic recovery scores was performed with the non-
Figure 2. Neurologic status 48 hours after unclamping as evaluated by the Johnson neurologic recovery scale.
Average scores represent mean ± SD. The figures 20-25, 30-55, and 30-35 shown along the axis of the graph of
groups A, C, and D indicate neurologic outcome every 5 minutes from 20 to 25 minutes, from 30 to 55 minutes, and
from 30 to 35 minutes of clamping, respectively. *P < .001 versus control after 30 minutes of clamping. #P = .014
versus control after 30 minutes of clamping.
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parametric Mann-Whitney U test. Statistical analyses of the mean
proximal arterial pressure, rectal temperature data, and the num-
bers of the remaining neurons were done with the unpaired t test.
Results
Neurologic Evaluation
Figure 2 represents the neurologic outcome in all groups.
The neurologic scores in group A were 3.6 ± 2.2, 0, and 0
after 20, 25, and 30 minutes of clamping, respectively. All
control animals in groups B, C, D, and E subjected to 30
minutes of clamping showed paraplegia (score 0). The neu-
rologic scores for dextrorphan-treated animals in group B
were 5.0 after 30 minutes of clamping, whereas they were 4.0
± 1.4, 3.4 ± 2.4, and 1.0 ± 2.2 after 35, 40, and 45 minutes of
clamping, respectively. The neurologic score for dextrorphan-
treated animals in group C was 5.0 after 30, 35, 40, 45, 50,
and 55 minutes of clamping, and the score was 3.3 ± 2.5 after
60 minutes of clamping. The neurologic score for dextror-
phan-treated animals in group D was 5.0 after 30 and 35 min-
utes of clamping, and the scores were 4.2 ± 0.8, 4.2 ± 1.1, and
1.6 ± 2.3 after 40, 45, and 50 minutes of clamping, respec-
tively. The neurologic scores for dextrorphan-treated animals
in group D were 5.0 after 25 minutes of clamping and 4.0 ±
2.2 and 0 after 30 and 40 minutes of clamping, respectively.
Comparison of Average Scores
Each dextrorphan-treated group showed better neurologic
function than their respective control group of animals after
30 minutes of clamping (P < .001 vs groups B, C, and D; P
= .014 vs group E). Groups B, C, and D showed better neu-
rologic function than group E (P = .017 vs group B; P <
.001 vs group C; P = .005 vs group D) after 40 minutes of
clamping. In addition, groups C and D showed better neu-
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rologic function than group B (P = .014 vs group C; P =
.044 vs group D) after 45 minutes of clamping. Further-
more, group C showed better neurologic function than
group D after 50 minutes of clamping (P = .017). Therefore,
among the dextrorphan-treated animals, those from group C
showed the best neurologic function, and continuous intra-
aortic infusion of dextrorphan prolonged the safe aortic
clamping time to 55 minutes (Figure 3).
Blood Pressure and Rectal Temperature
The mean arterial pressure was not affected by dextrorphan
or by the method of administration, except that group E
showed hypotension at 30 minutes (P < .05 vs groups A and
D; P < .001 vs group C) and 40 minutes (P < .01 vs group
C) after clamping (Table 1). Rectal temperature decreased
gradually after induction of anesthesia and continued to fall
during aortic clamping because we did not use heating pads.
There were no statistically significant differences among the
groups, except that group E showed a significant decrease of
rectal temperature at the point of aortic clamping and also
after 10 minutes (P < .01 vs groups A, C, and D; P < .05 vs
group B), 20 minutes (P < .05 vs groups A, B, and C), and
30 minutes of clamping (P < .05 vs groups A and B).
Histopathologic Evaluation
The spinal cords of animals that recovered fully (score 5)
after dextrorphan treatment were histologically well pre-
served with normal-looking motor neurons, which had clear
nucleoli and Nissl substance on hematoxylin and eosin
staining of cross sections of the lumbar spinal cord. On the
other hand, some spinal cords from the animals with hind-
limb paralysis (score 0) demonstrated necrotic changes,
including destruction and vacuolization of the gray matter,
pyknosis of neurons, and eosinophilic changes of the cyto-
plasm, but others appeared almost normal. However, it was
difficult to detect any obvious differences in the histologic
features of spinal cords with scores between 2 and 4 (Figure
4). The counts of remaining neurons apparently corre-
sponded to the average neurologic scores (Figure 5).
Discussion
Ischemic neuronal death in the spinal cord and in the brain
occurs because excessive glutamate release activates the glu-
tamate NMDA receptor and triggers intracellular Ca2+
influx.13 The efficacy of noncompetitive NMDA receptor
antagonists for prevention of neuronal ischemia has been doc-
umented, especially in the brain.4,5 Similar studies on the
spinal cord have also been conducted recently through intra-
venous,6,7,9-11 intra-aortic,9,10 and intraperitoneal routes.8
Dextrorphan, the O-demethylated metabolite of the com-
mon antitussive dextromethorphan, is an NMDA antagonist
that attenuates hypoxic neuronal injury in cultured cells and
significantly reduces ischemic neuronal injury in animal
Figure 3. Average scores for the neurologic recovery scale.
Standard deviations are eliminated. *P < .001 compared with
groups B, C, and D and P = .014 compared with group E after 30
minutes of clamping. **P < .001 compared with group C, P = .005
compared with group D, and P = .017 compared with group B after
40 minutes of clamping. #P = .014 compared with group C and
P = .044 compared with group D after 45 minutes of clamping. ##P
= .017 compared with group C after 50 minutes of clamping.
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stroke models.14 Pharmacokinetic studies have indicated
that intravenous dextrorphan has a mean half-life of 1.7 to
5.4 hours.15 Dextromethorphan is rapidly converted to dex-
trorphan, which is 5 times more effective against hypoxic
neuronal injury.16 In this study, dextrorphan was adminis-
tered by means of 4 different methods: continuous intra-
venous infusion, continuous intra-aortic infusion, bolus
intra-aortic injection, and bolus intrathecal injection. Each
of the 5 groups was divided into separate cohorts according
to their duration of clamping. At first, neurologic outcome
at 30 minutes of clamping was evaluated and then clamping
time was gradually lengthened at an increment of 5 minutes
(group B, C, and D) or 10 minutes at a time (group E) until
the neurologic status of the animals clearly deteriorated.
Control animals in all groups except group A became para-
plegic at 30 minutes of clamping. It was observed that the
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dextrorphan-treated animals of groups B, C, and D could
safely withstand crossclamping for up to 30 minutes,
whereas this duration for group E was 25 minutes. In our
study, dextrorphan was effective irrespective of the method
of administration when compared with control animals.
Continuous intra-aortic infusion was found to be the most
effective method, and it prolonged the safe clamping time
up to 55 minutes. Bolus intra-aortic injection was found to
be a little more effective than continuous intravenous infu-
sion. The reason for this efficacy probably is that intra-
aortic dextrorphan is delivered more effectively to the
ischemic spinal cord. However, the extent of neurologic
recovery showed some variation in both groups. Continuous
intra-aortic infusion led to a better outcome than bolus intra-
aortic injection, possibly because most of the dextrorphan
injected in one shot was washed away from spinal cord. In
TABLE 1. Mean proximal arterial pressure (mm Hg) during aortic clamping
Clamping time (min)
Before 10 20 30 40 50 60
Group A 91 ± 6 90 ± 8 88 ± 8 87 ± 9
Group B 94 ± 11 94 ± 9 85 ± 9 85 ± 8 89 ± 9
Group C 92 ± 8 89 ± 10 89 ± 10 90 ± 10 90 ± 10 90 ± 10 90 ± 7
Group D 95 ± 11 89 ± 11 89 ± 11 85 ± 11 82 ± 12 89 ± 14
Group E 89 ± 12 85 ± 13 85 ± 11 75 ± 9* 77 ± 13†
Values represent mean ± standard deviation. Group A (n = 15) received simple infrarenal aortic clamping; group B (n = 20), continuous intravenous infu-
sion of dextrorphan; group C (n = 35), continuous intra-aortic infusion of dextrorphan; group D (n = 25), bolus intra-aortic injection of dextrorphan; and
group E (n = 15), bolus intrathecal injection of dextrorphan.
*P < .05 versus groups A and D; P < .001 versus group C.
†P < .01 versus group C.
Figure 4. Representative photomicrographs of lumbar spinal cord sections from animals that received bolus intra-
aortic injection of dextrorphan and 50 minutes of clamping. Sections were stained with hematoxylin and eosin 48
hours after unclamping (original magnification 100×). The animals had hind-limb paralysis. Some spinal cords show
necrotic changes, including destruction and vacuolization of the gray matter, pyknosis of neurons, and eosinophilic
changes of the cytoplasm (A), and others show normal-looking motor neurons (B).
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this sense, bolus intra-aortic injection is similar to continu-
ous intravenous infusion. It has also been demonstrated that
dextrorphan must be continuously infused for adequate neu-
roprotection, because the drug failed to protect against
ischemic edema or neuronal damage when given as a load-
ing dose only, whereas a loading dose plus maintenance
infusion showed significant protection.17 In our study, bolus
intrathecal injection of dextrorphan was also effective
against spinal cord ischemia, but the safe clamping time was
not as long as we expected. Dextrorphan easily passes
through the blood-brain barrier, and the blood level corre-
lates well with the free brain level and with the extent of
protection against ischemic neuronal damage.18 Thus, dex-
trorphan may infiltrate the entire spinal cord more effec-
tively through the blood vessels than through the spinal
fluid. Continuous intrathecal infusion of dextrorphan may
prolong the safe clamping time, but it is difficult to insert an
intrathecal catheter. Several studies have been performed
with regard to percutaneous intrathecal injection in rats19
and rabbits.20 However, we found that percutaneous
intrathecal injection in rabbits was difficult because the
intrathecal space is very narrow. Blood pressure was stable
in all groups while the aorta was crossclamped.
Hypothermia can inhibit glutamate release21 and prolong
tolerance of ischemia.22 In this study, ischemia was induced
with normothermia. The temperature of all groups except
for the intrathecal group decreased spontaneously but was
not significantly lower than that of group A. Therefore,
hypothermia, which may have influenced the duration of the
safe clamping time, did not play a major role in protecting
the spinal cord from ischemia. Although the body tempera-
ture of the intrathecal group was significantly lower than in
other groups, this may be attributable to the preischemic fall
of temperature in this group. The reason for the preischemic
hypothermia was that the preischemic operating time was
Cardiopulmonary Support and Physiology Terada et al
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longer in the intrathecal group because of additional inva-
sive procedures. However, the rate of decrease in body tem-
perature in this group was similar to that in the other groups.
Histopathologic findings did not necessarily correspond
well with hind-limb neurologic function. Even the spinal cords
of paraplegic animals were sometimes histologically normal.
These results suggest that the mechanism of motor neuron
deficits is complex and that the spinal cords of paraplegic ani-
mals do not always show obvious necrosis. We counted only
the remaining neurons because necrotic neurons, which lost
nuclear hematoxylin, were difficult to distinguish from sur-
rounding tissue. Ortiz and associates23 described cytopatho-
logic changes in the cingulate cortex of rats treated with a
30-mg/kg dose of dextrorphan, and these animals did not
exhibit overt changes such as ataxia. The present study, how-
ever, revealed no obvious histopathologic changes in the ani-
mals that did not show any neurologic deficits.
It has also been reported that transient and reversible
adverse effects, including nystagmus, nausea, vomiting,
somnolence, hallucinations, agitation, and hypotension at
high doses, can occur in dextrorphan-treated patients with
acute stroke.15 However, such adverse effects resolve
rapidly after discontinuation of infusion because of the short
half-life of the drug, and dextrorphan does not exhibit any
cardiac or other systemic toxicities.15 No findings obviously
attributable to drug toxicity were noted in this study.
However, in the clinical situation attention should be paid to
such a possibility. It was demonstrated that preoperative8,9
and postoperative treatment17,18 with dextrorphan improved
the tolerance of the spinal cord to ischemia. Improvement in
neurologic outcome might also be expected in the clinical
situation because pretreatment of patients undergoing tho-
racic and thoracoabdominal aortic operations is possible.
Segmental sequential repair and distal aortic perfusion
with the aid of partial cardiopulmonary bypass is performed
in many hospitals including ours as a standard surgical treat-
ment for thoracoabdominal aortic aneurysms to shorten the
spinal ischemic time as much as possible.24-26 Hypothermic
circulatory arrest has been used when the location, extent, or
severity of aortic disease precludes placement of clamps on
the aorta.27 Nevertheless, postoperative neurologic deficits
are difficult to prevent completely, and supplementary pro-
cedures might be required. A multimodality protocol
described by Hollier and associates,28 which included cere-
brospinal fluid drainage, maintenance of proximal hyperten-
sion during crossclamping, and the use of mannitol, steroids,
and calcium channel blockers, appeared to be effective in
reducing the risk of spinal cord injury during thoracoabdom-
inal aortic replacement. We think the use of neuroprotective
drugs might add to the options in this regard. We assume that
continuous intravenous infusion of dextrorphan might be
comparable with continuous distal aortic perfusion (which is
used for cardiopulmonary bypass) because dextrorphan is
Figure 5. Neurons stained with hematoxylin and eosin in the gray
matter of lumbar spinal cord. *P < .001 versus other groups. **P <
.001 versus other groups except group A. #P = 0.013 versus group
C, and P = .009 versus group D.
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distributed systemically except in the crossclamped aortic
segment. Therefore, intravenous dextrorphan infusion is also
expected to prolong the safe clamping time. A thorough
application of our experimental procedure of continuous
intra-aortic infusion to the thoracoabdominal operation in
human beings is impossible. However, for the clinical use of
this continuous intra-aortic infusion method, selective inter-
costal arterial perfusion, either through a small Dacron pros-
thesis29 or through catheters of 1-mm or 1.5-mm diameter,30
might be helpful in achieving continuous infusion directly
into the intercostal arteries of the crossclamped aortic seg-
ment. However, insertion of such narrow catheters is often
time consuming, technically difficult, and associated with
risk of injury to the intercostal arteries. Continuous intrathe-
cal infusion via a catheter was impossible in rabbits, but
such intrathecal catheterization can be done percutaneously
in human beings. The procedure is likely to be more effec-
tive if two catheters are used, one for infusion and the other
for drainage.
The safe clamping time was prolonged in all of the dex-
trorphan-treated animals when compared with the control
animals. Continuous intra-aortic infusion of dextrorphan, in
particular, was able to prolong the safe aortic clamping
time, which was significantly longer than that provided by
any other route. The present experiment was done in an
infrarenal aortic clamping model rather than a thoracoab-
dominal aortic clamping model. However, the results of this
study suggest that dextrorphan has the potential to reduce
spinal cord ischemia in patients undergoing thoracoabdom-
inal aortic operations. Further clinical investigations are
required to determine the beneficial effects of dextrorphan.
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